Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 10/20 | 0.83 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.83 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.83 |
| ▸ | OXTR | P30559 | 7/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornipressin SCHEMBL1650220 | 0.97 | AVPR1A (0.88) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Ornipressin SCHEMBL296322 | 0.97 | AVPR1A (0.88) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL5199973 | 0.96 | AVPR1A (0.77) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Ornipressin SCHEMBL4410141 | 0.95 | AVPR1A (0.85) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL1650587 | 0.95 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL33287 | 0.95 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL29471105 | 0.94 | OXTR (0.84) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| SCHEMBL24239052 | 0.93 | OXTR (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL1650172 | 0.92 | AVPR1A (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL31138866 | 0.92 | AVPR1A (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773870-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | Novetide Ltd. (IL) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | AVPR1A 349/4885AVPR1B 376/4885AVPR2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.